Twist Bioscience (NASDAQ:TWST) Stock Price Target Lowered at Robert W. Baird

Twist Bioscience (NASDAQ:TWST) had its price objective trimmed by Robert W. Baird from $187.00 to $135.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other equities research analysts also recently commented on TWST. Jefferies Financial Group began coverage on Twist Bioscience in a report on Thursday, October 8th. They issued a “hold” rating and a $150.00 target price on the stock. Guggenheim raised their price target on Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Piper Sandler lifted their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. BWS Financial reiterated a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research note on Friday, September 18th. Finally, Canaccord Genuity Group cut their price objective on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $141.00.

Twist Bioscience Price Performance

TWST stock opened at $111.60 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The firm has a 50 day moving average price of $150.23 and a 200-day moving average price of $93.07. Twist Bioscience has a 52-week low of $23.30 and a 52-week high of $219.71. The firm has a market capitalization of $7.00 billion, a price-to-earnings ratio of -53.40 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The company had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. The business’s revenue was up 26.7% compared to the same quarter last year. Equities research analysts forecast that Twist Bioscience will post -1.52 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 356,546 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the transaction, the chief executive officer directly owned 620,589 shares of the company’s stock, valued at $98,046,856.11. This represents a 36.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 8,057 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,521,806.16. Following the sale, the chief financial officer directly owned 100,576 shares in the company, valued at $18,996,794.88. This trade represents a 7.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 495,279 shares of company stock worth $80,489,387 over the last three months. Company insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TWST. BlackRock Inc. purchased a new stake in Twist Bioscience during the 2nd quarter valued at $600,191,000. William Blair Investment Management LLC bought a new stake in shares of Twist Bioscience in the second quarter worth $223,722,000. Stephens Investment Management Group LLC grew its holdings in shares of Twist Bioscience by 1.7% in the third quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock worth $150,808,000 after acquiring an additional 13,055 shares during the period. Bank of America Corp DE purchased a new stake in Twist Bioscience during the second quarter valued at $94,922,000. Finally, Russell Investments Group Ltd. increased its position in Twist Bioscience by 190.8% during the third quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock valued at $54,863,000 after acquiring an additional 186,294 shares during the last quarter.

Key Headlines Impacting Twist Bioscience

These are some of the TWST headlines that stood out recently:

• Positive Sentiment: Fiscal Q4 revenue rose about 27% year over year to $126.6 million, beating consensus, while the $0.32-per-share loss was narrower than analysts expected. AI drug-discovery revenue totaled $59.1 million for fiscal 2026. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only modestly above the $549 million consensus, which may have disappointed investors looking for a stronger outlook. Article: Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
• Negative Sentiment: Leerink Partners cut its price target to $175 from $190, TD Cowen to $137 from $190, and Baird to $135 from $187. Each maintained a positive rating—outperform or buy—but the reductions indicate more cautious valuation expectations. Leerink Partners ratings

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.